Abstract OT-09-10: A Phase I/II Open-Label, First-in-human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects with Advanced And/or Metastatic Hormone Receptor (Hr)-Positive, HER2-negative Breast Cancer
Cancer research（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined